YaoGeJu

Company directoryChina company filings

Le Pu Pharmaceutical Technology Co., Ltd. romanized

Check drug filings and source records for this company-name string.

Listed by the company name as recorded in the source, without merging affiliated entities.

Page reference 0b1323d75c

Complete CDE snapshot
2026/11/13 06:42
Matching scope
Loaded public-source records only

These counts cover loaded acceptance records only. First-applicant and co-applicant counts are not added together. CDE data as of 2026/11/13 06:42.

Drug filings

12 acceptance records as first applicant, grouped into 12 source drug names. Source data as of 2026/11/13 06:42.

Acceptance records are de-duplicated by acceptance number. Drug names are normalized only for width and whitespace; dosage forms and combinations remain separate. Application types are retained from the source. Expand a drug to inspect each record. Published drugs link to their drug pages; other names do not create new public drug pages.

Atorvastatin Calcium Tablets 1 records · Latest accepted 2026/03/13

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2600509Supplement2026/03/13Le Pu Pharmaceutical Technology Co., Ltd. romanized; Zhejiang Le Pu Pharmaceutical Co., Ltd. romanizedCDE ↗
Ezetimibe and Atorvastatin Calcium Tablets(II) 1 records · Latest accepted 2024/07/10

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2402110Generic2024/07/10Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Epalrestat Tablets 1 records · Latest accepted 2023/08/22

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2302233Generic2023/08/22Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Ursodeoxycholic Acid Capsules 1 records · Latest accepted 2023/02/04

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300358Generic2023/02/04Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Ritonavir Tablets 1 records · Latest accepted 2023/01/06

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2300048Generic2023/01/06Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Tofacitinib Citrate Extended Release tablets 1 records · Latest accepted 2022/02/10

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200286Generic2022/02/10Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
依折麦布匹伐他汀钙片 · No verified English name 1 records · Latest accepted 2022/01/24

New drug · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CXHL2200044New drug2022/01/24Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Oseltamivir Phosphate For Oral Suspension 1 records · Latest accepted 2022/01/14

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2200069Generic2022/01/14Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Doxazosin Mesylate Extended Release Tablets 1 records · Latest accepted 2021/12/15

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2102208Generic2021/12/15Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Acarbose Tablets 1 records · Latest accepted 2021/08/16

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2101686Supplement2021/08/16Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Rosuvastatin Calcium Tablets 1 records · Latest accepted 2021/08/11

Generic · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHS2101541Generic2021/08/11Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
乳酸菌素片 · No verified English name 1 records · Latest accepted 2021/07/20

Supplement · 1

Drug filings
Acceptance numberApplication typeAcceptedCompany / applicantView source
CYHB2101582Supplement2021/07/20Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗

Changes in the last 90 days

0 events from 2026/08/16 to 2026/11/13. CDE data as of 2026/11/13 06:42; NMPA data as of 2026/11/12 18:32.

This source was last successfully updated at 2026/11/12 18:32; current coverage may be incomplete.

Last 90 days, ordered by fact date. Marketing approvals, trial registrations, supplements, notices and review changes are labelled separately. Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

  1. No matching records were found in the currently loaded source data; coverage dates are listed below.

Under review

1 acceptance numbers with this company as first applicant are currently listed as under review by CDE. Source data as of 2026/11/13 06:42.

Under review
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Atorvastatin Calcium Tablets CYHB2600509Supplement2026/03/13Le Pu Pharmaceutical Technology Co., Ltd. romanized; Zhejiang Le Pu Pharmaceutical Co., Ltd. romanizedCDE ↗

Catalogue holder records

10 loaded active catalogue records whose holder name matches this source company name. Source data as of 2026/11/13 06:39. Manufacturer-only records are excluded.

DrugMarketing authorization holderManufacturerApproval numberApprovedCatalogue category (source text)View source
Ezetimibe and Atorvastatin Calcium Tablets(II)Le Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202564202025/12/30Generic approved under the new chemical-drug registration classificationCDE ↗
Epalrestat TabletsLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202535342025/03/04Generic approved under the new chemical-drug registration classificationCDE ↗
Ursodeoxycholic Acid CapsulesLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202493932024/11/15Generic approved under the new chemical-drug registration classificationCDE ↗
Ritonavir TabletsLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202441702024/06/28Generic approved under the new chemical-drug registration classificationCDE ↗
Oseltamivir Phosphate For Oral SuspensionLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202430802024/01/23Generic approved under the new chemical-drug registration classificationCDE ↗
Tofacitinib Citrate Extended Release tabletsLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202341252023/09/05Generic approved under the new chemical-drug registration classificationCDE ↗
Doxazosin Mesylate Extended Release TabletsLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202339642023/07/25Generic approved under the new chemical-drug registration classificationCDE ↗
Rosuvastatin Calcium TabletsLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202337782023/06/27Generic approved under the new chemical-drug registration classificationCDE ↗
Sitagliptin Phosphate TabletsLe Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202232352022/04/19Generic approved under the new chemical-drug registration classificationCDE ↗
Valsartan and Amlodipine Tablets(I)Le Pu Pharmaceutical Technology Co., Ltd. romanizedLe Pu Pharmaceutical Technology Co., Ltd. romanized国药准字H202230732022/02/18Generic approved under the new chemical-drug registration classificationCDE ↗

Only active catalogue records matching the source holder name are listed. A manufacturer role does not count as a holder record. The catalogue covers only part of the chemical-drug market; source categories do not establish complete market coverage or qualifications.

API registrations

0 loaded active API registrations whose first registered company matches this source company name. Source data as of 2026/11/13 06:41.

NameCompany / applicantRegistration numberStatusSource update dateView source
No matching records were found in the currently loaded source data; coverage dates are listed below.

Only loaded active API registrations not listed as cancelled are shown. A/I are source registration statuses. Records are listed by registration number and do not establish capacity or supply. The register does not identify the associated formulation.

Co-applicant records

8 acceptance records name this company after the first applicant. They are listed separately and are not included in first-applicant drug or filing counts. Source data as of 2026/11/13 06:42.

Co-applicant records
Drug Acceptance numberApplication typeAcceptedCompany / applicantView source
Milnacipran Hydrochloride Tablets CYHS2600586Generic2026/02/28Zhejiang Hua Bei Pharma Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate and Aspirin Tablets(Ⅱ) CYHS2500185Generic2025/01/09Pu Ji Bio Technology (Tai Zhou) Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Pentoxifylline Modified Release Tablets CYHS2400712Generic2024/02/29Pu Ji Bio Technology (Tai Zhou) Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Amlodipine Besylate and Benazepril Hydrochloride Capsules CYHS2400478Generic2024/02/05Name not romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Vortioxetine Hydrobromide Tablets CYHS2400134Generic2024/01/10Pu Ji Bio Technology (Tai Zhou) Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Vortioxetine Hydrobromide Tablets CYHS2400133Generic2024/01/10Pu Ji Bio Technology (Tai Zhou) Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
Nitroglycerin Sublingual Tablets CYHS2302396Generic2023/09/06Nanjing Si Tai Er Pharmaceuticals Technology Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗
瑞巴派特片 · No verified English name CYHS2201755Generic2022/10/18Xi Zhou Pharmaceuticals Technology (Zhejiang) Co., Ltd. romanized; Le Pu Pharmaceutical Technology Co., Ltd. romanizedCDE ↗

How current is each source?

CDE acceptances and review
Last successful update: 2026/11/13 06:42
Chemical-drug catalogue
Last successful update: 2026/11/13 06:39
Full API register
Last successful update: 2026/11/13 06:41
NMPA drug delivery notices
Last successful update: 2026/11/12 18:32 · Current coverage may be incomplete

First index-page publication dates: 2026-10-29 to 2026-11-13; 2 pages pending. Covers loaded notices only, not a complete historical approval database.

Listed by the company name as recorded in the source, without merging affiliated entities.

This page summarizes loaded records only, without new source queries or collection. Parent companies, subsidiaries, former names and aliases are not merged. Counts from different sources must not be added together. No loaded record does not establish the absence of a filing or registration. Check original records where coverage is incomplete, an update has failed, or a source lies outside the loaded scope.

Fact dates are approval dates, acceptance dates, trial first-publication dates or complete-snapshot observation dates, as applicable. Publication and site-observation dates are separate. Historical backfills are not current-period new events. Exit records cover currently inactive applications with an identifiable complete snapshot, not a full review history.

Drugs with a verified official English name use that name only. Other drug names retain the Chinese source name marked No verified English name; names with a Chinese public page link to that page. Company labels use verified official names, Latin source names, then fixed-rule transliterations marked romanized; Chinese company names are not displayed. Marked unverified drug names and original statutory reference numbers may appear in Chinese.

Legal reference identifiers are retained verbatim. Company labels use official English entries where available, or a visibly marked fixed romanization. Unverified drug names retain the Chinese source name with a No verified English name marker. Other Chinese free text is not displayed; use the source links or source-name columns in CSV exports.